Add to a list

Suspension of trading

Rayont Inc. Stock

RAYT

US75508M1009

Biotechnology & Medical Research

OTC Markets Traded

Market Closed - OTC Markets 15:16:38 2024-11-15 EST			5-day change	1st Jan Change
0.000001 ^USD	-100.00%		-.--%	-

23-05-15	Rayont Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	CI
23-02-24	Rayont Inc. Announces Board Appointments	CI

Rayont Inc. operates in the personalized natural healthcare sector in United States and Australia. The Company uses scientific tools, such as deoxyribonucleic acid (DNA), microbiome, iridology and other tests to diagnose and personalize the prescription of natural complementary medicine products, services and treatments to its patients in the markets the Company operate. The Company produces a range of products, including proteins, green blends, sports nutrition, weight management and maintenance, and health and wellness products. The Company's subsidiaries include Rayont (Malaysia) Sdn Bhd, Rayont International (L) Limited, Rayont (Australia) Pty Ltd and Prema Life (USA) Inc.

Employees

Sector

Biotechnology & Medical Research

More about the company

Stock Market
Stocks
RAYT Stock

As early as today, start finding the best investment opportunities!

Market Cap	4.47M 4.01M 3.66M 3.34M 6.3M 420M 6.5M 44.15M 17.61M 224M 16.77M 16.41M 708M	P/E 2021	293x	P/E 2022	186x
Enterprise Value	12.25M 10.99M 10.04M 9.17M 17.27M 1.15B 17.81M 121M 48.26M 614M 45.98M 44.99M 1.94B	EV / Sales 2021	47.8x	EV / Sales 2022	18.8x
Free-Float	48.18%	Yield 2021 *	-	Yield 2022	-

23-05-15	Rayont Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	CI
23-02-24	Rayont Inc. Announces Board Appointments	CI
23-02-14	Rayont Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022	CI
23-01-17	Rayont Inc. Reports Earnings Results for the First Quarter Ended September 30, 2022	CI
22-12-29	Rayont Inc. Reports Earnings Results for the Full Year Ended June 30, 2022	CI
22-12-28	Rayont Inc. Auditor Raises 'Going Concern' Doubt	CI
22-05-20	Rayont Inc. Appoints Ilenna Copley as Chief Operating Officer	CI
22-05-17	Rayont Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2022	CI
22-04-25	Rayont Inc. Announces Management Changes	CI
22-04-22	Rayont Inc. Announces Board Resignations	CI
22-03-01	Rayont Inc. Announces Management Changes	CI
22-03-01	Rayont Inc. Announces Executive Changes	CI
22-02-24	Rayont Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2021	CI

23-06-23	Rayont : Non-Reliance on Previously Issued Financial Report - Form 8-K	PU
23-06-23	RAYONT INC. : Non-Reliance on Previous Financials, Audits or Interim Review, Financial Statements and Exhibits (form 8-K)	AQ
23-05-05	RAYONT INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)	AQ
23-03-31	RAYONT INC. : Financial Statements and Exhibits (form 8-K)	AQ
23-02-24	RAYONT INC. : Change in Directors or Principal Officers (form 8-K)	AQ

3 years	0		0.1
5 years	0		2.5
10 years	0		10.4

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
RAYONT INC.	-100.00%	-.--%	-	-	45
WUXI APPTEC CO., LTD.	-4.83%	+3.51%	+55.00%	+63.79%	66.7B
ARGENX SE	+0.02%	+1.07%	+11.72%	+75.63%	56.88B
LONZA GROUP AG	-1.34%	+2.98%	+25.08%	+100.18%	56.53B
BEONE MEDICINES AG	+5.09%	+9.89%	+27.19%	+105.85%	46.49B
IQVIA HOLDINGS INC.	+2.62%	+1.68%	+29.16%	+35.86%	44.8B
REVOLUTION MEDICINES, INC.	+8.24%	+0.51%	+215.16%	+794.74%	41.59B
CELLTRION, INC.	-1.86%	+10.13%	+28.14%	+55.48%	35.35B
GENMAB A/S	-2.97%	-9.84%	+90.91%	+73.49%	33.29B
INSMED INCORPORATED	+5.19%	+1.62%	-39.69%	+368.87%	25.1B
Average	-8.98%	+2.38%	+49.18%	+185.99%	40.67B
Weighted average by Cap.	+0.65%	+3.07%	+49.90%	+165.88%

Rayont Inc. Stock

Stocks

RAYT

US75508M1009

Biotechnology & Medical Research

Valuation: Rayont Inc.

Latest news: Rayont Inc.

Press Releases: Rayont Inc.

Quotes and Performance

Price Extremes

Other Biotechnology & Medical Research

Financials

Company Profile

	2021	2022
Net sales	2.97M 2.66M 2.43M 2.22M 4.19M 279M 4.32M 29.34M 11.7M 149M 11.15M 10.91M 470M	2.84M 2.55M 2.33M 2.12M 4M 267M 4.13M 28.05M 11.19M 142M 10.66M 10.43M 450M
Net income	384K 344K 315K 287K 541K 36.09M 558K 3.79M 1.51M 19.25M 1.44M 1.41M 60.79M	245K 220K 201K 183K 345K 23.02M 356K 2.42M 965K 12.28M 919K 899K 38.77M
Net Debt	2.4M 2.16M 1.97M 1.8M 3.39M 226M 3.5M 23.75M 9.47M 121M 9.02M 8.83M 381M	7.78M 6.98M 6.38M 5.82M 10.97M 731M 11.31M 76.87M 30.65M 390M 29.2M 28.58M 1.23B